DCGI approval

The drug is also effective for viruses causing viral respiratory infections

The launch follows the product’s approval by the Drugs Controller General of India (DCGI) for use of Trelegy Ellipta as…

The company will initiate the trial by June 2022 to determine the safety, tolerability and preliminary anti-tumour activity of the…

The EUA application was submitted on 22nd March by Prakash Kumar Singh, Director, Government and Regulatory Affairs, SII

The authorisation is a global first for the age group for the vaccine, which is manufactured and marketed by the Serum Institute…

It is now approved as monotherapy for adjuvant treatment after complete tumour resection in patients with NSCLC

It is a topical solution that will cost Rs 1850 for a week’s treatment, and can reportedly help prevent amputation

The company informed that these tablets, to be marketed under brand name Favizen, will be manufactured with in-house API

Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be…

A multi-centric, open label, two-arm randomized pivotal clinical trial was conducted in 30 eligible patients at four hospitals…